肿瘤抑制和抗炎蛋白:胰岛素降解酶(IDE)的扩展观点
Tumor suppressor and anti-inflammatory protein: an expanded view on insulin-degrading enzyme (IDE)
摘要:
在1994年,我证实胰岛素降解酶(IDE)作为恶性转化的抑制剂,通过降解胰岛素,从而阻止这种主要的生长刺激激素结合,从而使视网膜母细胞瘤肿瘤抑制蛋白(RB)失活。十年后,我发现RB的羧基末端有一段氨基酸序列与IDE的催化中心很相似。这种结构同源性提出了胰岛素降解是RB和IDE共有的肿瘤抑制的基本机制的可能性。随后,首次对人IDE在正常组织、原发性肿瘤及其相应淋巴结转移中的差异表达进行免疫组织化学研究,进一步证实了IDE是一种β分子的初步推测。在这份报告中,它表明,IDE港口锚蛋白重复样氨基酸序列,通过它可能会结合,因此,拮抗促炎因子NF-κ B以及细胞周期蛋白依赖性激酶(CDK)。如本文同样揭示的,IDE还含有2个RXL细胞周期蛋白结合基序,这可能有助于其对CDK的假定抑制。这些新的发现表明,IDE可能能够通过几种机制抑制炎症和肿瘤发生,最终确保RB功能。
英文摘要:
In 1994, I conjectured that insulin-degrading enzyme (IDE) acts as an inhibitor of malignant transformation by degrading insulin and thus preventing this major growth-stimulatory hormone from binding and thereby inactivating the retinoblastoma tumor suppressor protein (RB). Ten years later, I discovered that a carboxyterminal RB amino acid sequence resembles the catalytic center of IDE. This structural homology raised the possibility that insulin degradation is a basic mechanism for tumor suppression shared by RB and IDE. Subsequently, a first immunohistochemical study on the differential expression of human IDE in normal tissues, primary tumors and their corresponding lymph node metastases further corroborated the initial conjecture on IDE being an antineoplastic molecule. In this report, it is shown that IDE harbors ankyrin repeat-like amino acid sequences through which it might bind and, as a result, antagonize the pro-inflammatory factor NF-kappaB as well as cyclin-dependent kinases (CDKs). As equally revealed here, IDE also contains 2 RXL cyclin-binding motifs which could contribute to its presumed inhibition of CDKs. These new findings suggest that IDE is potentially able to suppress both inflammation and oncogenesis by several mechanisms that ultimately ensure RB function.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。